Gastrointestinal disease drug developer Phathom raised almost $182m in an initial public offering that involved Takeda bumping up its equity stake in the company.
US-based gastrointestinal disease therapy developer Phathom Pharmaceuticals went public on Friday in an initial public offering sized at approximately $182m while pharmaceutical firm Takeda boosted its stake.
The company increased the number of shares in the offering from 7.9 million to approximately 9.56 million and priced them at $19.00 each, in the middle of the $18 to $20 range it set last week. It floated on the Nasdaq Global Select Market.
Phathom is developing therapeutics intended to treat…
